What is AbbVie?
Global biopharmaceutical leader in immunology, neuroscience, oncology, and aesthetics
- Category
- Biopharmaceuticals
- Headquarters
- North Chicago, Illinois
- Founded
- January 1, 2013
- Employees
- ~60,000 globally
- Revenue (FY2025)
- $61.2 billion
- Market Cap (June 2026)
- ~$381 billion (NYSE: ABBV)
What is AbbVie?
AbbVie is a global, research-based biopharmaceutical company that discovers, develops, and commercializes medicines for complex and serious diseases across immunology, neuroscience, oncology, and aesthetics. Spun off from Abbott Laboratories on January 1, 2013, the company generated $61.2 billion in net revenues in full-year 2025 — an 8.6% year-over-year increase — and is one of the five largest pharmaceutical companies in the world by revenue. Its products are sold in more than 170 countries, and the immunology portfolio alone exceeded $30 billion in 2025 net revenues, led by Skyrizi ($17.6 billion) and Rinvoq ($8.3 billion).
AbbVie was built on Humira (adalimumab), which peaked at over $21 billion in annual global sales and was the world's best-selling drug for nearly a decade. Following Humira's loss of U.S. exclusivity in January 2023, which triggered rapid biosimilar erosion, AbbVie successfully executed one of the most closely watched transitions in pharmaceutical history: its next-generation immunology drugs Skyrizi (risankizumab) and Rinvoq (upadacitinib) together generated $25.9 billion in 2025 — surpassing Humira's all-time peak by more than $4.5 billion. The pivot validated a multi-year indication expansion strategy that now spans rheumatoid arthritis, atopic dermatitis, psoriasis, Crohn's disease, and ulcerative colitis.
The company's portfolio was dramatically expanded via the $63 billion acquisition of Allergan in May 2020, which added Botox (therapeutic and cosmetic), Juvederm, Vraylar, and Ubrelvy. The neuroscience portfolio — Botox Therapeutic, Vraylar (cariprazine), Ubrelvy (ubrogepant), and Qulipta (atogepant) — generated $10.8 billion in 2025, a 19.6% year-over-year increase. Oncology contributed $6.7 billion, anchored by Imbruvica (ibrutinib) and Venclexta (venetoclax), and the aesthetics segment (Botox Cosmetic, Juvederm) added $4.9 billion.
As of Q1 2026, AbbVie reported net revenues of $15.0 billion (+12.4% year-over-year) and raised its full-year 2026 revenue guidance to approximately $67.3 billion. The company has approximately 60,000 employees, invests roughly $8–9 billion annually in R&D, and holds a market capitalization of approximately $381 billion as of mid-June 2026. Chairman and CEO Robert A. Michael, who took the helm in July 2024, is executing an accelerated pipeline strategy that includes the $10.1 billion ImmunoGen acquisition (oncology, closed February 2024) and the $8.7 billion Cerevel Therapeutics acquisition (neuroscience, closed August 2024).
What does AbbVie offer?
AbbVie's commercial portfolio spans six major therapeutic areas and includes more than 30 marketed products, with over 50 additional compounds in clinical development.
- Skyrizi (risankizumab)· Immunology
- Rinvoq (upadacitinib)· Immunology
- Humira (adalimumab)· Immunology
- Botox Therapeutic· Neuroscience
- Vraylar (cariprazine)· Neuroscience
- Ubrelvy (ubrogepant)· Neuroscience
- Qulipta (atogepant)· Neuroscience
- Imbruvica (ibrutinib)· Oncology
- Venclexta (venetoclax)· Oncology
- Elahere (mirvetuximab soravtansine)· Oncology
- Botox Cosmetic· Aesthetics
- Juvederm· Aesthetics
- Mavyret (glecaprevir/pibrentasvir)· Infectious Disease
- Eye Care Pipeline· Ophthalmology
How does AbbVie make money?
AbbVie is a prescription pharmaceutical and biologics company that generates revenue by selling branded specialty drugs at high list prices, capturing value through proprietary intellectual property, broad patent estates, and managed-care contracts. Its commercial model varies by segment: the specialty pharma channel serves immunology, neuroscience, and oncology, while aesthetics products are sold directly to physicians at list prices with minimal payer intermediation.
Revenue is almost entirely product-based. Wholesalers and specialty distributors purchase AbbVie drugs at the Wholesale Acquisition Cost (WAC) and dispense them through pharmacies, hospital systems, and infusion centers. AbbVie's immunology blockbusters carry high annual list prices: Skyrizi is priced at approximately $23,838 per injection dose, while Humira's WAC before biosimilar entry was roughly $84,000 per patient per year. After rebates negotiated with pharmacy benefit managers and payers — which historically reached 60–85% on Humira — net realized prices are substantially lower, but the gross-to-net spread remains the defining lever for profitability. Skyrizi and Rinvoq together produced $25.9 billion in 2025 net revenues with lower rebate exposure than Humira's legacy position, supporting strong adjusted operating margins.
The aesthetics segment (Botox Cosmetic, Juvederm) operates under a fundamentally different model: products are sold directly to physicians and licensed aesthetic providers at list price with minimal payer intermediation, making it margin-rich but volume-sensitive to macroeconomic cycles. This segment contributed $4.9 billion in 2025, down 6.1%, as consumer discretionary spending softened — Botox Cosmetic delivered $2.6 billion and Juvederm $993 million. The neuroscience segment (Botox Therapeutic, Vraylar, Ubrelvy) follows the specialty-pharma channel model, with Vraylar commanding an annual list price above $40,000 and Botox Therapeutic billed per-unit in clinical settings; the segment generated $10.8 billion in 2025, growing 19.6% year-over-year.
Growth is driven by indication expansion — Skyrizi added Crohn's disease and ulcerative colitis to its label alongside plaque psoriasis — life-cycle management, and targeted acquisitions. AbbVie's full-year 2026 adjusted diluted EPS guidance stands at $14.08–$14.28 (raised after Q1 2026 beat), implying strong adjusted operating margins. The company spends approximately $8–9 billion per year on R&D and has deployed more than $18.8 billion in transformative acquisitions between 2023 and 2024 alone (ImmunoGen at $10.1 billion and Cerevel at $8.7 billion), reflecting a disciplined external-innovation model under CBSO Nicholas Donoghoe.
Who leads AbbVie?
AbbVie is led by Chairman and CEO Robert A. Michael, who succeeded founding CEO Richard Gonzalez in July 2024 and was elevated to Chairman in July 2025. The executive team spans finance, operations, R&D, commercial, and legal functions across a $61+ billion revenue business.
- Robert A. MichaelChairman and Chief Executive OfficerCEO since July 1, 2024; Chairman since July 1, 2025Former President and COO of AbbVie; joined post-spin in 2013 to build the company's first financial planning organization, then rose through commercial and operational leadership over more than a decade.
- Richard A. GonzalezFounding CEO and Chairman (retired)CEO 2013–2024; Chairman 2013–2025Architect of the AbbVie spin-off and the Allergan acquisition; spent 30+ years at Abbott before leading AbbVie as its first CEO through transformative acquisitions and the Humira peak.
- Scott T. ReentsExecutive Vice President and Chief Financial OfficerCFO since 2018Oversees global finance, treasury, tax, and investor relations; has been a key steward of AbbVie's capital allocation through the Allergan integration and the post-Humira pivot.
- Roopal Thakkar, M.D.Executive Vice President, Research & Development and Chief Scientific OfficerEVP R&D and CSO since July 10, 2024; 20+ years at AbbVieLeads a global R&D organization of more than 14,000 team members across all phases of discovery and development, including six major R&D centers across the U.S., Germany, and Japan; succeeded Thomas Hudson upon his retirement.
- Azita Saleki-Gerhardt, Ph.D.Executive Vice President and Chief Operations OfficerEVP COO; with AbbVie/Abbott since 1993Oversees global manufacturing, supply chain, engineering, quality, and enterprise services across AbbVie's 10+ country manufacturing footprint.
- Nicholas Donoghoe, M.D.Executive Vice President and Chief Business and Strategy OfficerCBSO since 2023Leads business development, corporate strategy, and business technology operations; oversaw the ImmunoGen ($10.1B) and Cerevel ($8.7B) acquisitions closed in 2024.
- Perry C. SiatisExecutive Vice President, General Counsel and SecretaryEVP General Counsel since October 2022Oversees global legal, ethics and compliance, and government affairs organizations; promoted from SVP and Deputy General Counsel to EVP in 2022.
- Jeffrey R. StewartExecutive Vice President and Chief Commercial OfficerCCO since 2019Leads global commercial operations including sales, marketing, market access, and pricing across all therapeutic areas and the Allergan Aesthetics business unit.
How do you contact AbbVie's leadership?
AbbVie's verified email format is firstname.lastname@abbvie.com, used by the large majority of employees per ContactOut, RocketReach, and LeadIQ. Real published contact channels include investors.abbvie.com and news.abbvie.com. The addresses below for named executives follow the verified company format and are inferred, not individually confirmed.
firstname.lastname@abbvie.comHow much funding has AbbVie raised?
AbbVie is a publicly traded company (NYSE: ABBV) and has not raised traditional venture or private equity funding. It was spun off from Abbott Laboratories on January 1, 2013, and finances transformative acquisitions through investment-grade debt markets and generates over $17 billion annually in free cash flow. Its market capitalization stood at approximately $381 billion as of mid-June 2026.
AbbVie debuted on the NYSE on January 2, 2013, with an initial market cap of approximately $54 billion. Since then, the company has self-financed through operating cash flows and debt capital markets rather than equity rounds. To fund its $21 billion acquisition of Pharmacyclics in May 2015, AbbVie issued significant term loans and senior notes. To finance the $63 billion Allergan acquisition announced June 2019 and closed May 2020, AbbVie issued approximately $30 billion in senior unsecured notes across multiple tranches — one of the largest bond offerings in pharmaceutical history. This brought AbbVie's pro-forma net debt at closing to approximately $80 billion.
Following the Allergan deal, AbbVie rapidly deleveraged through operating cash flows. The company generated approximately $17.8 billion in free cash flow in 2025, and paid $11.7 billion in dividends, representing a 65.4% free cash flow payout ratio. Two additional acquisitions closed in 2024 deployed a combined $18.8 billion: ImmunoGen ($10.1 billion, closed February 2024, adding Elahere for ovarian cancer) and Cerevel Therapeutics ($8.7 billion, closed August 2024, adding a neuroscience pipeline). Both were funded through operating cash flows and incremental debt.
In Q1 2026, AbbVie filed a Form 424B5 with the SEC for a new offering of senior unsecured notes, reflecting continued use of investment-grade debt markets for pipeline acquisitions and general corporate purposes. With full-year 2026 revenue guidance raised to approximately $67.3 billion and adjusted diluted EPS guidance of $14.08–$14.28, AbbVie is one of the most highly valued pharmaceutical companies globally at a market capitalization of approximately $381 billion as of mid-June 2026.
How did AbbVie get here?
AbbVie's history spans from its 2013 birth as an Abbott spin-off through blockbuster drug launches, multi-billion-dollar acquisitions, and a successful post-Humira pivot to Skyrizi and Rinvoq that validated its long-term growth strategy.
- January 1, 2013AbbVie spins off from Abbott LaboratoriesAbbVie begins trading on NYSE under ticker ABBV, anchored by Humira — then the world's top-selling drug — with Richard Gonzalez as founding CEO and an initial market cap of approximately $54 billion.
- May 22, 2015Acquires Pharmacyclics for $21 billionAbbVie outbids Johnson & Johnson to acquire Pharmacyclics and its flagship asset Imbruvica (ibrutinib), immediately establishing a leading position in hematologic oncology and giving AbbVie a co-promotion partnership with Janssen.
- June 25, 2019Announces $63 billion acquisition of AllerganThe transformative deal adds Botox (therapeutic and cosmetic), Juvederm, Vraylar, Ubrelvy, and other assets to AbbVie's portfolio, funded with approximately $30 billion in senior unsecured notes — one of the largest bond issuances in pharma history.
- May 8, 2020Allergan acquisition closesFollowing FTC approval and Irish High Court proceedings, AbbVie completes the Allergan deal and creates Allergan Aesthetics as a dedicated global business unit; pro-forma net debt reaches approximately $80 billion at closing.
- January 2023Humira biosimilars enter U.S. marketTen adalimumab biosimilars launch in the U.S.; Humira revenues decline sharply over 2023–2025, but are more than offset by accelerating Skyrizi and Rinvoq growth, vindicating AbbVie's years-long successor strategy.
- February 2024Acquires ImmunoGen for $10.1 billionAbbVie closes its $10.1 billion acquisition of ImmunoGen, adding Elahere (mirvetuximab soravtansine) — a first-in-class antibody-drug conjugate approved for platinum-resistant ovarian cancer — and a pipeline of next-generation ADCs to its oncology portfolio.
- August 1, 2024Acquires Cerevel Therapeutics for $8.7 billionAbbVie closes its $8.7 billion acquisition of Cerevel Therapeutics, adding a clinical-stage neuroscience pipeline targeting schizophrenia, Parkinson's disease, and mood disorders, accelerating the neuroscience franchise beyond legacy Botox and Vraylar.
- July 1, 2024 / July 1, 2025Robert A. Michael becomes CEO, then ChairmanMichael succeeds Gonzalez as CEO on July 1, 2024; on July 1, 2025, he is also elevated to Chairman of the Board. AbbVie reports full-year 2025 revenues of $61.2 billion and raises 2026 guidance to $67.3 billion under Michael's tenure.
Who are AbbVie's competitors?
AbbVie competes across immunology, oncology, neuroscience, and aesthetics with a range of large-cap pharmaceutical and biotech companies. The most direct threat in immunology is Regeneron and Sanofi's Dupixent franchise, now tracking toward $16+ billion annually in indications directly overlapping Rinvoq.
- Johnson & JohnsonCompetes directly in immunology (Stelara, Tremfya) and oncology (Darzalex, Erleada); also contested AbbVie for Pharmacyclics in 2015 and competes in Crohn's disease — one of Skyrizi's fastest-growing indications.
- PfizerCompetes in immunology with Cibinqo (atopic dermatitis) and has biosimilar programs targeting Humira's legacy position; also a major oncology rival with a broad hematology and solid-tumor portfolio.
- Regeneron PharmaceuticalsDupixent (dupilumab), co-developed with Sanofi, is the fastest-growing rival to Rinvoq in atopic dermatitis and asthma; Dupixent is on track for $16+ billion in annual sales and directly competes across multiple Rinvoq and Skyrizi indications.
- Bristol Myers SquibbCompetes in immunology (Sotyktu, Orencia) and oncology; Revlimid and Opdivo are strong oncology franchises overlapping with AbbVie's hematology portfolio. Sotyktu (deucravacitinib) directly targets psoriasis, one of Skyrizi's lead indications.
- Eli LillyGrowing immunology rival with Taltz (plaque psoriasis and psoriatic arthritis) and Olumiant (JAK inhibitor in rheumatoid arthritis); also a major competitor in migraine neuroscience with Emgality.
- AmgenMajor biosimilar producer for Humira (Amjevita was among the first U.S. biosimilar launches in January 2023) and competes in oncology and inflammation; also a structural immunology competitor with Enbrel in rheumatoid arthritis.
AbbVie — frequently asked questions
